Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL) filed this Current Report on Form 8-K on June 8, 2022. The filing provides an update on the Company's allogeneic CAR T cell therapy pipeline and its liquidity position as of May 31, 2022.
Key Financial Metrics
- Cash and Cash Equivalents: Approximately $121 million as of May 31, 2022 (unaudited).
- Liquidity Runway: Management expects existing cash, operational receipts, and available credit to fund operations into mid-2023.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or margin figures for this period.
- Debt: The filing mentions "available credit" but does not specify outstanding debt amounts.
Material Changes and Clinical Updates
The Company reported significant interim data for its Phase 1/2a study of PBCAR0191, an allogeneic CD19 CAR T therapy for relapsed aggressive lymphomas:
- Efficacy (ASH and New Cohorts): Achieved a 100% overall response rate (11/11 evaluable subjects) and a 73% complete response rate (8/11).
- New Cohort Performance: Subjects treated with reduced intensity lymphodepletion (DL4b) achieved a 100% complete response rate (5/5 evaluable).
- Duration of Response: In the ASH Cohort, 50% of subjects had a response duration greater than six months; six subjects remain in ongoing response (up to 18+ months).
- Safety Profile: No Grade 3 or greater cytokine release syndrome (CRS) was observed. Grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in one subject per cohort but resolved rapidly. Two Grade 5 events related to late-occurring encephalopathy (suspected fludarabine-associated) occurred in the New Cohort. No graft versus host disease was observed.
- Infection Rates: Grade 3 or greater infections were less frequent in the New Cohort (17%) compared to the ASH Cohort (67%).
Updates on other pipeline candidates include:
- PBCAR19B: Dosing of the next cohort (DL2) is expected to commence in the third quarter of 2022 following manufacturing optimization.
- PBCAR269A: The Company is initiating the next cohort (DL3) in combination with nirogacestat for multiple myeloma. Peak expansion rates at DL2 plus GSI were equivalent to higher dose monotherapy with no dose-limiting toxicities.
Guidance, Outlook, and Risks
The Company plans to continue enrolling subjects in the PBCAR0191 study in the second half of 2022 and expects to provide updates on PBCAR0191, PBCAR19B, and PBCAR269A toward year-end. The filing includes standard forward-looking statements regarding the development of the CAR T pipeline and the projected cash runway, noting risks related to clinical trial outcomes and financial sufficiency.
Investor Verification Checklist
- Verify the $121 million cash balance and the mid-2023 liquidity runway against the most recent audited financial statements (Form 10-Q).
- Review the full press release (Exhibit 99.1) for detailed safety data regarding the two Grade 5 encephalopathy events.
- Monitor the timeline for the PBCAR19B DL2 dosing commencement in Q3 2022.
- Confirm the status of the "available credit" facility mentioned in the liquidity assessment.